GILD vs. ALNY: Which Stock Is the Better Value Option?

Core Viewpoint - The article compares Gilead Sciences (GILD) and Alnylam Pharmaceuticals (ALNY) to determine which stock is more attractive to value investors [1] Valuation Metrics - GILD has a forward P/E ratio of 12.35, while ALNY has a significantly higher forward P/E of 659.03 [5] - GILD's PEG ratio is 1.31, indicating a more favorable valuation relative to its expected earnings growth, compared to ALNY's PEG ratio of 20.24 [5] - GILD's P/B ratio stands at 6.30, contrasting sharply with ALNY's P/B of 1,062.58, suggesting GILD is more aligned with its book value [6] Investment Outlook - Both GILD and ALNY currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions for both companies [3] - GILD is rated with a Value grade of A, while ALNY has a Value grade of D, suggesting GILD is the superior value option based on current metrics [6]